New combo therapy aims to keep aggressive lung cancer at bay
NCT ID NCT04745689
Summary
This study is testing whether a two-drug combination (AZD2811 and durvalumab) can help control extensive stage small-cell lung cancer when given as ongoing 'maintenance' therapy after initial chemotherapy. The trial involves about 31 adults whose cancer hasn't worsened after first-line treatment. Researchers want to see if this maintenance approach keeps the cancer from progressing longer and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Grand Rapids, Michigan, 49503, United States
-
Research Site
Bydgoszcz, 85-796, Poland
-
Research Site
Olsztyn, 10-357, Poland
-
Research Site
Poznan, 60-693, Poland
-
Research Site
Cheongju-si, 28644, South Korea
-
Research Site
Jinju, 52727, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Seville, 41071, Spain
-
Research Site
Valencia, 46015, Spain
Conditions
Explore the condition pages connected to this study.